Further cash for GSK shareholders as Aspen fronts £164 million for RoW OTC products
This article was originally published in Scrip
Executive Summary
South African company Aspen has agreed to acquire a basket of over-the-counter products from GlaxoSmithKline for R2.1 billion (£164 million), for markets outside Europe and North America. The products, which include Phillips Milk of Magnesia, the pain relief brand Solpadeine, the low-dose aspirin Cartia, the antiseptic brand Dequadin and the antacid Zantac (ranitidine), generated sales in the territories concerned of about £60 million last year.